anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The rate of vitamin D deficiency (VDD) in critically ill children worldwide has been estimated at 50%. These children are at risk of multiple organ dysfunction, chronic morbidity, and decreased health related quality of life (HRQL). Pediatric and adult ICU clinical trials suggest that VDD is associated with worse clinical outcomes, although data from supplementation trials are limited and inconclusive. Our group's phase II multicenter dose evaluation pilot study established the efficacy and safety of an enteral weight-based cholecalciferol loading dose to rapidly restore vitamin D levels in critically ill children.
METHODS: Our aim is to evaluate the impact of this dosing regimen on clinical outcomes. VITdALIZE-KIDS is a pragmatic, phase III, multicenter, double-blind RCT aiming to randomize 766 critically ill children from Canadian PICUs. Participants are randomized using a 1:1 scheme to receive a single dose at enrollment of enteral cholecalciferol (10,000 IU/kg, max 400,000 IU) or placebo. Eligibility criteria include critically ill children aged newborn (> 37 weeks corrected gestational age) to < 18 years who have blood total 25-hydroxyvitamin D < 50 nmol/L. The primary objective is to determine if rapid normalization of vitamin D status improves HRQL at 28 days following enrollment. The secondary objective is to evaluate the impact of rapid normalization of vitamin D status on multiple organ dysfunction. The study includes additional tertiary outcomes including functional status, HRQL and mortality at hospital discharge and 90 days, PICU and hospital length of stay, and adverse events related to vitamin D toxicity. Additionally, we are performing comprehensive vitamin D speciation and non-targeted metabolite profiling as part of a sub-study for the first 100 participants from whom an enrollment and at least one post-intervention blood and urine sample were obtained.
DISCUSSION: The VITdALIZE-KIDS trial is the first phase III, multicenter trial to evaluate whether rapid normalization of vitamin D status could represent a simple, inexpensive, and safe means of improving outcomes following pediatric critical illness. Recruitment was initiated in June 2019 and is expected to continue to March 2026.
TRIAL REGISTRATION: Clinicaltrials.gov, NCT03742505. Study first submitted on November 12, 2018 https://clinicaltrials.gov/study/NCT03742505.
BACKGROUND: Adverse perinatal outcomes such as preterm, small for gestational age, low birth weight, congenital anomalies, stillbirth and neonatal death have devastating impacts on individuals, families and societies, with significant lifelong health implications. Despite extensive knowledge of the significant and lifelong health implications of adverse perinatal outcomes, information on the economic burden is limited. Estimating this burden will be crucial for designing cost-effective interventions to reduce perinatal morbidity and mortality. Thus, we will quantify the economic burden of adverse perinatal outcomes from births to age 5 years in high-income countries.
METHODS AND ANALYSIS: A systematic review of all primary studies published in English in peer-reviewed journals on the economic burden for at least one of the adverse perinatal outcomes in high-income countries from 2010 will be searched in databases-MEDLINE (Ovid), EconLit, CINAHL (EBSCO), Embase (Ovid) and Global Health (Ovid). We will also search using Google Scholar and snowballing of the references list of included articles. The search terms will include three main concepts-costs, adverse perinatal outcome(s) and settings. We will use the Consolidated Health Economics Evaluation Reporting Standards 2022 and 17 criteria from the critical appraisal of cost-of-illness studies to assess the quality of each study. We will report the findings based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 statement. Costs will be converted into a common currency (US dollar), and we will estimate the pooled cost and subgroup analysis will be done. The reference lists of included papers will be reviewed.
ETHICS AND DISSEMINATION: This systematic review will not involve human participants and requires no ethical approval. The results of this review will be published in a peer-reviewed journal.
PROSPERO REGISTRATION NUMBER: CRD42023400215.
The study aims to compare the use of hypothermia in patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) with control. We systematically searched four electronic databases until March 2022. The inclusion criteria were any study design that compared hypothermia in patients with MI undergoing PCI with control. The risk of bias assessment of the included randomized controlled trials was conducted through Cochrane Tool, while the quality of the included cohort studies was assessed by the NIH tool. The meta-analysis was performed on RevMan. A total of 19 studies were entered. Regarding the mortality, there were nonsignificant differences between hypothermia and control (odds ratio [OR] = 1.06, 95% confidence interval [CI] 0.75 to 1.50, p = 0.73). There was also no significant difference between the control and hypothermia in recurrent MI (OR = 1.21, 95% CI 0.64 to 2.30, p = 0.56). On the other hand, the analysis showed a significant favor for hypothermia over the control infarct size (mean difference = -1.76, 95% CI -3.04 to -0.47, p = 0.007), but a significant favor for the control over hypothermia in the overall bleeding complications (OR = 1.88, 95% CI 1.11 to 3.18, p = 0.02). Compared with the control, hypothermia reduced the infarct size of the heart, but this finding was not consistent across studies. However, the control had lower rates of bleeding problems. The other outcomes, such as death and the incidence of recurrent MI, were similar between the two groups.
Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI and the ondansetron is then repeated for more than seven days. In another method, an SRI, a neuroleptic, and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI, the neuroleptic, and the ondansetron is then repeated for more than seven days. In another method, ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder for more than seven days. The ondansetron or pharmaceutically acceptable salt thereof may be administered as a pharmaceutically effective dose up to about 1.5 mg (free-base equivalent).
The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.
The invention provides devices and methods to fabricate nanoparticles by reverse micelle and related methods, and applications for these nanoparticles. The method allows to fabricate a myriad of high quality nanoparticles in a repeatable way. These nanoparticles include multilayered spherical and rodlike particles that may have inorganic, organic, polymeric, biological layers. The invention further provides methods to optimize the quality of the nanoparticles. The fabrication method is based on accurate control of the microfluidics, and the chemical composition of the reaction mixture (203). This is made possible by an in-line monitoring system and microprocessor control of the various physical and chemical parameters. In the method pure solvent (501) is pumped into the perimeter of the capillary tube (504) parallel with the reagent solutions (201, 202).
This is an open-label (all people know the identity of the intervention), randomized (study medication assigned to participants by chance), 3- or 4-way crossover (participants may receive different interventions sequentially during the trial), and single-center study of ibrutinib. The duration of study will be approximately 67 to 83 days per participant. The study consists of 3 parts: Screening (28 days before study commences on Day 1); Open-label Treatment (consists of 6 treatments, either Ibrutinib capsule or suspension or sprinkle capsule granules under fed or fasted condition), in subsequent 3 periods for Group 1 and 4 periods for Group 2, each separated with washout period of 7 (plus \[+\] / minus \[-\] 2) days; and follow up Phase (up to 10 + / - 2 days after last study drug administration). All the eligible participants will be randomly assigned to 1 of the 6 (Group 1) or 4 (Group 2) treatment sequences. In fasted conditions, study drug will be administered following a 10-hour overnight fast. In fed conditions, participants will also fast from food for 10 hours, but will consume a high fat breakfast within a 30-minute period. Study drug will be administered 2 hours after the breakfast. Participants will not be allowed to have food until 4 hours of drug administration. Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment. Relative bioavailability of Ibrutinib will be evaluated primarily. Participants' safety will be monitored throughout the study.
In non-neural tissues (during CT of the body), Conray diffuses rapidly from the vascular to the extra-vascular space. Increase in x-ray absorption is related to blood flow, concentration of the contrast medium and extraction of the contrast medium by interstitial tissue, since no barrier exists; contrast enhancement is thus due to the relative differences in extra-vascular diffusion between normal and abnormal tissue, a situation quite different than that in the brain. 

The pharmacokinetics of Conray in normal and abnormal tissues has been shown to be variable. 

Enhancement of CT with Conray may be of benefit in establishing diagnoses of certain lesions in some sites with greater assurance than is possible with unenhanced CT and in supplying additional features of the lesions. In other cases, the contrast medium may allow visualization of lesions not seen with CT alone or may help to define suspicious lesions seen with unenhanced CT. 

Contrast enhancement appears to be greatest within the 30 to 90 seconds after bolus administration of the contrast agent, and after intra-arterial, rather than intravenous, administration. Therefore, the use of a continuous scanning technique (a series of 2 to 3 second scans beginning at the injection - dynamic CT scanning) may improve enhancement and diagnostic assessment of tumors and other lesions, such as an abscess, occasionally revealing more extensive disease. A cyst, or similar non-vascularized lesion, may be distinguished from vascularized solid lesions by comparing enhanced and unenhanced scans; non-vascularized lesions show no change in CT number, whereas vascularized lesions would show an increase. The latter might be benign, malignant or normal, but it is unlikely that it would be a cyst, hematoma, or other non-vascularized lesion. 

Because unenhanced scanning may provide adequate information in the individual patient, the decision to employ contrast enhancement, which is associated with additional risk and increased exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings.
The present invention discloses an extract from branches and leaves of yews and an extraction method. The extract mainly contains polysaccharide ingredients. The extract mainly contains heteropolysaccharide which is composed of D-glucose, a small quantity of D-xylose, arabinose, galactoside and glucuronic acid, and beta-1, 3 glycosidic bond; a small quantity of beta-1, 6 glycosidic bond branches exists on a main chain of beta-1, 3 glucan. The extract has the functions of immunological regulation and cancer resistance of directly inhibiting tumour cells, etc., and the toxic side effect of the extract is little. Through the experimental research for the effect of resisting tumour in vivo and in vitro, the extract has the good function of inhibiting S180 ascites carcinoma of Kunming mice. The extract has the good application prospect for developing anticancer drugs. The present invention adopts a polarity gradient method to properly separate ingredients in a solvent extraction process. Different kinds of effective ingredients, such as taxanes, flavonoid, steroid, lignin, etc., in yews can also be extracted by the technology.
A composition comprising plant extracts is provided to be usefully used for improving skin wrinkle by promoting collagen synthesis and having no cell toxicity and skin stability. The skin wrinkle improving composition comprises at least one extract selected from the group consisting of an extract of Forsythia koreana, an extract of Pteridium aquilinum var. latiusculum, an extract of Aralia elata, an extract of Oenanthe javanica, an extract of Mentha arvensis var. piperascens, an extract of Allium tuberosum, an extract of Houttuynia cordata, an extract of Rhododendron indicum, an extract of Sanquisorbae officinalis L., an extract of maize leaves, an extract of green peas, an extract of Brassica campestris subsp. napus var. nippo-oleifera, an extract of Sasa borealis, and an extract of Taraxacum platycarpum H. DAHLST. Each of the dried extract as much as 0.001-10.0 wt.% of the total weight is contained in the composition.
Atomoxetine HCl is a selective norepinephrine reuptake inhibitor. Atomoxetine hydrochloride is the R(-) isomer as determined by x-ray diffraction. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. The molecular formula is C17H21NO•HCL, which corresponds to a molecular weight of 291.82. The chemical structure is:

Atomoxetine hydrochloride USP is a white to practically white solid, which is sparingly soluble in water. Atomoxetine capsules, USP are intended for oral administration only.

Each capsule contains atomoxetine hydrochloride USP, equivalent to 10, 18, 25, 40, 60, 80 or 100 mg of atomoxetine. The capsules also contain pregelatinized starch, dimethicone. The capsule shells contain one or more of the following: FD&C Blue No. 2, gelatin, iron oxide red, iron oxide yellow,sodium lauryl sulfate and titanium dioxide. The capsules are imprinted with edible black ink. The edible black ink contains black iron oxide E172, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
This study is collecting blood and tissue samples (biospecimens) from people living with HIV, who are participating in an AIDS Malignancy Consortium (AMC) clinical trial. Biospecimens are also collected from people who are not living with HIV, but who have a type of cancer that is common in persons living with HIV. The National Cancer Institute created the AIDS and Cancer Specimen Resource (ACSR), a place where these tissue samples are stored, so researchers can learn more about how to treat HIV and related diseases. The AMC works with the AIDS and Cancer Specimen Resource (ACSR) to collect donated samples from people living with HIV or who have cancers that are associated with HIV for future research studies. People who do not take part in an AMC clinical trial can donate samples to the ACSR.

Individuals who agree to participate will be asked to donate blood once. Their blood will be stored in a biobank, and used for research. Individuals may also donate tissue - either from a previous procedure, or from an upcoming procedure.
Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
If asthma symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief. 

Patients 18 Years of Age and Older: For patients 18 years of age and older, the recommended starting dosage is 360 mcg twice daily. In some adult patients, a starting dose of 180 mcg twice daily may be adequate. The maximum dosage should not exceed 720 mcg twice daily.

Patients 6 to 17 Years of Age: The recommended starting dosage is 180 mcg twice daily. In some pediatric patients, a starting dose of 360 mcg twice daily may be appropriate. The maximum dosage should not exceed 360 mcg twice daily. 

For all patients, it is desirable to titrate to the lowest effective dose after adequate asthma stability is achieved.

Improvement in asthma control following inhaled administration of budesonide can occur within 24 hours of initiation of treatment, although maximum benefit may not be achieved for 1 to 2 weeks, or longer. Individual patients will experience a variable onset and degree of symptom relief. 

If a previously effective dosage regimen of PULMICORT FLEXHALER fails to provide adequate control of asthma, the therapeutic regimen should be re-evaluated and additional therapeutic options (e.g. replacing the lower strength of PULMICORT FLEXHALER with the higher strength or initiating oral corticosteroids) should be considered.
PURPOSE: It was designed to identify the symptom clusters and sentinel symptoms among patients with breast cancer receiving chemotherapy at the community level, and to explore core and bridge symptoms at the global level.
METHODS: A cross-sectional survey was conducted using the MD Anderson Symptom Inventory. Patients with breast cancer receiving chemotherapy, recruited from the "Be Resilient to Breast Cancer" project between January 2023 and December 2023, were included in the study. Symptom clusters and their sentinel symptoms were identified using exploratory factor analysis and Apriori algorithm. Core and bridge symptoms were identified using network analysis.
RESULTS: A total of 468 patients with breast cancer participated in the current study. At the community level, three symptom clusters and their corresponding sentinel symptoms were identified: a gastrointestinal symptom cluster (with nausea as the sentinel symptom), a psycho-sleep-related symptom cluster (with distress as the sentinel symptom), and a neurocognition symptom cluster (with dry mouth as the sentinel symptom). At the global level, fatigue emerged as the core symptom, while disturbed sleep and lack of appetite as bridge symptoms.
CONCLUSION: Addressing nausea, distress, and dry mouth are imperative for alleviating specific symptom clusters at the community level. Furthermore, targeting fatigue, disturbed sleep, and lack of appetite are crucial to break the interactions among diverse symptoms at the global level.
The invention relates to triple oral vaccine for cultivating marine fishes. The triple oral vaccine is prepared by mixing pharmaceutical starch, maltodextrin, vibrio parahaemolyticus broth with the concentration of 1*1012cfu, vibrio alginolyticus broth with the concentration of 1*1012cfu and edwardsiella tarda broth with the concentration of 1*1012cfu in the ratio of 3 to 1 to 0.35 to 0.35 to 0.35 according to the unit mode being g:g:ml:ml:ml. The invention relates to a preparation method of the triple oral vaccine, comprising the following steps of: (1) inactivating; (2) preparing pellets; (3) preparing an enteric coated layer lagging coating; and (4) coating phagostimulant in a spraying way. The invention relates to a use method of the triple oral vaccine, wherein the use method comprises the following steps of: (1) firstly feeding and (2) intentinonally feeding. According to the preparation method provided by the invention, the vibrio parahaemolyticus broth, the vibrio alginolyticus broth and the edwardsiella tarda broth trigeminy oral vaccine can be prepared. A feeding and vaccinating method is used, so that the triple oral vaccine is ideal in immune effect, and small in workload, thereby being suitable for vaccination on a large scale. Meanwhile, the triple oral vaccine provided by the invention adopts a functional coating material, so that the vaccine can not be digested within the gastric juice, and the vaccine can be quickly released within the intestinal tract; and therefore, the immune response can be generated, and the high-efficiency immune effect can be obtained.
This study is a cross sectional monocentric retrospective study in a geriatric day hospital population coming for frailty and cardio vascular evaluation : clinical data of 148 patients hospitalized from April 2018 to December 2019 (20 months) of the Measurement of the ARterial-Cardiac AGEing and prevention evaluation of FRailty (MARCAGE.FR) geriatric day hospital of Nancy were retrospectively analyzed. Eligible patients were those who had benefited from an EndoPAT® measurement and arterial stiffness evaluation and aged over 60 years. Exclusion criteria to analyze aortic pulse wave velocity was the presence of atrial fibrillation and for EndoPAT® a poor quality of the signal. 105 among these 148 patients were finally selected as they present EndoPAT® good signal (reviewed by two operators).

All subjects arrived in a fasting state at the geriatric day hospital where anthropometric, frailty evaluation, hemodynamic and transcutaneous measurements of aortic pulse wave velocity (AoPWV) were performed at rest. Some of them had a cerebral Magnetic resonance imaging (MRI) examination. Participants were requested not to smoke or drink tea or coffee for 30 minutes and to sit quietly for 10 minutes at least, before blood pressure and other hemodynamic parameters were measured. Individuals were considered hypertensive if they had systolic blood pressure (SBP) values \> 150 mm Hg and/or diastolic blood pressure (DBP) values \> 90 mm Hg or if they were previously diagnosed as hypertensive and treated with one or more antihypertensive drug.
Treatment will consist of ketogenic diet. KGD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.